A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
breast and ovarian cancer
health services delivery
integrated knowledge translation
interdisciplinary research
oncogenetics
prevention
screening
treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 May 2021
31 May 2021
Historique:
received:
24
02
2021
revised:
12
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Medical genetic services are facing an unprecedented demand for counseling and testing for hereditary breast and ovarian cancer (HBOC) in a context of limited resources. To help resolve this issue, a collaborative oncogenetic model was recently developed and implemented at the CHU de Québec-Université Laval; Quebec; Canada. Here, we present the protocol of the C-MOnGene (Collaborative Model in OncoGenetics) study, funded to examine the context in which the model was implemented and document the lessons that can be learned to optimize the delivery of oncogenetic services. Within three years of implementation, the model allowed researchers to double the annual number of patients seen in genetic counseling. The average number of days between genetic counseling and disclosure of test results significantly decreased. Group counseling sessions improved participants' understanding of breast cancer risk and increased knowledge of breast cancer and genetics and a large majority of them reported to be overwhelmingly satisfied with the process. These quality and performance indicators suggest this oncogenetic model offers a flexible, patient-centered and efficient genetic counseling and testing for HBOC. By identifying the critical facilitating factors and barriers, our study will provide an evidence base for organizations interested in transitioning to an oncogenetic model integrated into oncology care; including teams that are not specialized but are trained in genetics.
Identifiants
pubmed: 34072979
pii: cancers13112729
doi: 10.3390/cancers13112729
pmc: PMC8198545
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Oncopole
ID : 296057
Références
Am Soc Clin Oncol Educ Book. 2019 Jan;39:79-86
pubmed: 31099688
Fam Cancer. 2019 Jul;18(3):293-301
pubmed: 30689103
Breast Cancer Res Treat. 2010 Jan;119(2):409-14
pubmed: 19885732
Asia Pac J Clin Oncol. 2020 Apr 20;:
pubmed: 32309911
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Ann Surg Oncol. 2007 Dec;14(12):3335-44
pubmed: 17541692
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
Oncogene. 2004 Aug 23;23(38):6445-70
pubmed: 15322516
Implement Sci. 2014 Dec 18;9:168
pubmed: 25518730
N Engl J Med. 2002 May 23;346(21):1609-15
pubmed: 12023992
J Clin Oncol. 2005 Jan 10;23(2):276-92
pubmed: 15637391
J Genet Couns. 2018 Feb;27(1):16-20
pubmed: 29052810
Cell Oncol (Dordr). 2011 Apr;34(2):71-88
pubmed: 21336636
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
JAMA. 2001 Nov 14;286(18):2251-6
pubmed: 11710890
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
JAMA. 2019 Aug 20;322(7):652-665
pubmed: 31429903
Ann Intern Med. 2014 Feb 18;160(4):271-81
pubmed: 24366376
J Health Polit Policy Law. 2000 Dec;25(6):1083-120
pubmed: 11142053
Br J Cancer. 2018 Jul;119(2):141-152
pubmed: 29867226
J Med Genet. 2018 Sep;55(9):571-577
pubmed: 30042185
JAMA. 2006 May 24;295(20):2374-84
pubmed: 16720823
BMC Med Res Methodol. 2018 Nov 19;18(1):143
pubmed: 30453902
J Clin Oncol. 2017 Jul 10;35(20):2329-2337
pubmed: 28398847
Med Decis Making. 2003 Jul-Aug;23(4):281-92
pubmed: 12926578
Breast. 2014 Dec;23(6):721-42
pubmed: 25467311
N Engl J Med. 2001 Jul 19;345(3):159-64
pubmed: 11463009
Pharmacoeconomics. 1998 Mar;13(3):277-88
pubmed: 10178653
Cancers (Basel). 2018 Nov 13;10(11):
pubmed: 30428547
Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4
pubmed: 21908500
Breast Cancer Res Treat. 2019 Jan;173(2):313-318
pubmed: 30311024
CA Cancer J Clin. 2017 Nov;67(6):493-506
pubmed: 28881380
Int J Mol Sci. 2017 Jan 31;18(2):
pubmed: 28146134
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
J Clin Oncol. 2013 Nov 20;31(33):4188-98
pubmed: 24145348
Ann Surg Oncol. 2018 Nov;25(12):3556-3562
pubmed: 30167906
Curr Oncol. 2019 Feb;26(1):e17-e23
pubmed: 30853805
J Genet Couns. 2014 Apr;23(2):239-53
pubmed: 24158360
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
JAMA Netw Open. 2019 May 3;2(5):e194428
pubmed: 31125106
Health Aff (Millwood). 2018 May;37(5):710-716
pubmed: 29733704
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Am J Prev Med. 2017 Nov;53(5):e195-e196
pubmed: 29054246